LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE; NEVIRAPINE
Pre-Launchlamivudine; tenofovir disoproxil fumarate; nevirapine
NDAORALTABLET
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
This is a fixed-dose combination tablet containing three antiretroviral agents: lamivudine (nucleoside reverse transcriptase inhibitor), tenofovir disoproxil fumarate (nucleotide reverse transcriptase inhibitor), and nevirapine (non-nucleoside reverse transcriptase inhibitor). The combination is indicated for HIV-1 treatment by targeting viral replication through complementary mechanisms. This oral tablet formulation simplifies regimen complexity for patient adherence.
Pre-Launch
Pre-launch stage offers opportunity to build market presence in a competitive antiretroviral space; commercial team buildout and launch planning are currently underway.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on this pre-launch product offers ground-floor opportunity to build commercial infrastructure in a globally significant HIV treatment market with established demand. Career growth depends on successful launch execution, market penetration, and establishing Aurobindo's position in antiretroviral therapy.
Brand ManagerCommercial Launch Manager
Worked on LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE; NEVIRAPINE at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.